The Stockholm Material Hub, of which Sigrid Therapeutics is a long-term collaborator of, receives €0.5 M boost from European Regional Development Fund
Sigrid Therapeutics today announced that the Stockholm Material Hub, a long-term collaboration partner of the Company, has secured €0.5 million funding from the EU’s European Regional Development Fund. The funding period covers 2020-2024 and will enable continued breakthrough research into novel materials and their use in life science applications.
The goal of the Stockholm Material Hub (SMH) is to bridge the curiosity-driven fundamental research with entrepreneurship-motivated social practices through needs-driven research. Coordinated by Stockholm University (SU) the hub integrates materials expertise existing in Royal Institute of Technology (KTH), Karolinska Institute (KI) and other academic institutions. The vision of the hub is to become the core source of knowledge in the general field of materials research, consistently spinning off innovation either through the establishment of new SMEs and strengthening the existing local SMEs, thus contributing to the economic growth of the Stockholm region. SMH is led by a highly experienced team consisting of Professor James Shen, Aji Mathew and Mirva Eriksson at Stockholm University.
“Our own research at the Department of Material and Environmental Chemistry (MMK) is focusing on developing new materials for a sustainable society, employing green synthesis and sustainable processing routes. The MMK department has a long-standing track record of developing novel materials for life science applications. Sigrid has been a valued, long-term research partner of ours and this funding enables us to continue to provide the complex R&D support Sigrid’s material development requires,” comments Professor Shen.
“Professor James Shen and his research group are world leaders in the research and development of novel materials. We are delighted to learn that the Stockholm Material Hub has received this funding”, says Sana Alajmovic, CEO Sigrid Therapeutics. “For us, this means that we will be able to continue our fruitful collaboration and expand our project portfolio based on our SiPoreTM platform technology, with continued access to cutting edge-physiochemical characterization equipment and some of the most skilled material researchers out there.”
For more information, please contact: Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics Phone +46 72 389 3396, Email: [email protected]
About Sigrid Therapeutics Sigrid Therapeutics (Sigrid) is a clinical-stage technology startup pioneering a new class of engineered materials to prevent and treat metabolic disease and disorders, including type 2 diabetes. The Company’s lead product candidate, SiPore15TM, is an orally-administered medical device based on the Company’s proprietary platform technology, SiPoreTM. Designed to act locally in the gut, SiPore15TM, consists of precisely engineered micron-sized silica particles with tailored porosity. Clinical data confirms SiPore15 TM’s beneficial effects on a range of metabolic parameters and its excellent safety profile. Upon its approval, SiPore15 TM will be the first medical device available for reduction of blood sugar levels in people at risk of developing type 2 diabetes. https://www.sigridthx.com/
About the European Regional Development Fund (ERDF) The ERDF aims to strengthen economic and social cohesion in the European Union by correcting imbalances between its regions. The ERDF focuses its investments on several key priority areas, known as ‘thematic concentration’: 1) Innovation and research; 2) The digital agenda; 3) Support for small and medium-sized enterprises (SMEs) and 4)The low-carbon economy. For more information, see https://ec.europa.eu/regional_policy/en/funding/erdf/.
